Clinical Trial Update: Long-term Extension Study of MCI-196 [Phase 3]

View source ↗

Summary

A terminated Phase 3 long-term extension study of MCI-196 in chronic kidney disease patients; the trial status has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• End-stage Renal Disease
• Hyperphosphatemia

Drugs mentioned

• MCI-196

Snippet

Sponsor: Tanabe Pharma Corporation | Conditions: Chronic Kidney Disease, Dialysis | Phase 3 | Status: TERMINATED